Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
-1.72%
)
Bitcoin
70,287.00
(
-0.32%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 123710

Thursday, 01/19/2012 7:27:49 AM

Thursday, January 19, 2012 7:27:49 AM

Post# of 257268
NVS starts phase-3 trials for Neupogen/Neulasta FoB’s:

http://www.novartis.com/newsroom/media-releases/en/2012/1578463.shtml

These programs seek FDA regulatory approval via the traditional BLA pathway, not the new 351(k) pathway, which implies that they will be non-substitutable for the corresponding branded products from AMGN.

Teva is also a player in the market for Neopogen/Neulasta FoB’s, and it reached a partial patent settlement with AMGN (#msg-65841959, #msg-65308970).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today